Global Blood Therapeutics, Inc., a biopharmaceutical company, engages in the discovery, development, and commercialization of novel therapeutics to treat grievous blood-based disorders. Its product candidate is GBT440, a hemoglobin modifier that binds to hemoglobin molecules, which is in double-blind Phase I/II clinical trial indicated for the treatment of sickle cell disease. The company also focuses on developing an oral prophylactic therapy for hypoxemic pulmonary disorders and hereditary angioedema. The company was founded in 2011 and is headquartered in South San Francisco, California.
Reason for the jump today: Global Blood, FDA Reach Agreement on Pivotal Trial Design for Sickle Cell Disease Drug Source: https://www.thestreet.com/story/138...rial-design-for-sickle-cell-disease-drug.html
$GBT https://www.marketbeat.com/stocks/N...m_source=GeneralSocialMedia&utm_medium=Social Ratings Breakdown:6 Buy Ratings Consensus Rating:Buy (Score: 3.00) Consensus Price Target:$48.44 (80.06% upside)
GBT Reports Recent Business Progress and Provides Third Quarter 2017 Financial Results http://bit.ly/2h7OBks
